MIRA Pharmaceuticals (NASDAQ:MIRA) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS

MIRA Pharmaceuticals (NASDAQ:MIRA) issued its quarterly earnings data on Friday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.14, Zacks reports.

MIRA Pharmaceuticals Stock Down 3.6 %

Shares of NASDAQ MIRA opened at $1.06 on Friday. The stock has a market cap of $17.55 million, a P/E ratio of -1.89 and a beta of 2.31. The firm’s 50-day simple moving average is $1.12 and its 200 day simple moving average is $1.22. MIRA Pharmaceuticals has a fifty-two week low of $0.51 and a fifty-two week high of $5.01.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.